{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:10:30Z","timestamp":1788811830468,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tacrolimus is a cornerstone immunosuppressant in kidney transplantation with a narrow therapeutic index and high interindividual pharmacokinetic variability, largely determined by CYP3A4, CYP3A5, and P-glycoprotein activity. Grapefruit juice is a known intestinal CYP3A4 inhibitor capable of increasing tacrolimus exposure, whereas blood orange juice has not been documented to exert such effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 33-year-old male kidney transplant recipient of Somali origin had persistently low tacrolimus trough levels, averaging about 4.5\u00a0\u00b5g\/L, despite increased dosing. On postoperative day 5 (POD 5), the patient consumed approximately one liter of blood orange juice followed later the same evening by a clinically supervised 250\u00a0mL dose of grapefruit juice intended to enhance tacrolimus exposure. The following morning, his tacrolimus concentration had risen sharply sixfold to 30\u00a0\u00b5g\/L, far above the increase typically associated with grapefruit juice alone. Kidney biopsy at that time showed eosinophilic infiltration, consistent with a drug-related inflammatory reaction. Tacrolimus therapy was temporarily stopped, then gradually reintroduced. His condition stabilized, and he was discharged on POD 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The pronounced increase in tacrolimus exposure following sequential ingestion of blood orange and grapefruit juice suggests a potential synergistic interaction affecting tacrolimus disposition via CYP3A4, CYP3A5 and\/or P-glycoprotein pathways. While causality remains unconfirmed, this case emphasizes the value of thorough dietary history in transplant care and supports further research on blood orange juice as a possible modulator of tacrolimus pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06514-w","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:04:51Z","timestamp":1788807891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe rise in tacrolimus levels following blood orange and grapefruit juice intake in a kidney transplant recipient: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5767-5015","authenticated-orcid":false,"given":"Victoria","family":"\u00d6stman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Lorant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"10","key":"6514_CR1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"6514_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513\u201322.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"6514_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127995","volume":"10","author":"WL Shi","year":"2015","unstructured":"Shi WL, Tang HL, Zhai SD. Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS ONE. 2015;10(6): e0127995.","journal-title":"PLoS ONE"},{"issue":"7","key":"6514_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2217\/pgs.11.33","volume":"12","author":"M Miura","year":"2011","unstructured":"Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics. 2011;12(7):977\u201384. https:\/\/doi.org\/10.2217\/pgs.11.33.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"6514_CR5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.transproceed.2006.02.079","volume":"38","author":"SH Akbas","year":"2006","unstructured":"Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc. 2006;38(5):1290\u20132. https:\/\/doi.org\/10.1016\/j.transproceed.2006.02.079.","journal-title":"Transplant Proc"},{"issue":"4","key":"6514_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15990","volume":"90","author":"S Armani","year":"2024","unstructured":"Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug\u2013drug interactions. Br J Clin Pharmacol. 2024;90(4):942\u201358. https:\/\/doi.org\/10.1111\/bcp.15990.","journal-title":"Br J Clin Pharmacol"},{"key":"6514_CR7","unstructured":"Research C for DE and. Drug development and drug interactions | Table of Substrates, Inhibitors and Inducers. FDA. 2024. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 14 Apr 2026."},{"issue":"1","key":"6514_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-6-33","volume":"6","author":"J Kiani","year":"2007","unstructured":"Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J. 2007;6(1): 33. https:\/\/doi.org\/10.1186\/1475-2891-6-33.","journal-title":"Nutr J"},{"issue":"3","key":"6514_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.775","volume":"9","author":"SC Trenaman","year":"2021","unstructured":"Trenaman SC, Bowles SK, Andrew MK, Goralski K. The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharmacol Res Perspect. 2021;9(3): e00775.","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"6514_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"6514_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00228-009-0702-z","volume":"65","author":"C Liu","year":"2009","unstructured":"Liu C, Shang YF, Zhang XF, Zhang XG, Wang B, Wu Z, et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J Clin Pharmacol. 2009;65(9):881\u20135. https:\/\/doi.org\/10.1007\/s00228-009-0702-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"6514_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1503\/cmaj.120951","volume":"185","author":"DG Bailey","year":"2013","unstructured":"Bailey DG, Dresser G, Arnold JMO. Grapefruit\u2013medication interactions: forbidden fruit or avoidable consequences? CMAJ Can Med Assoc J. 2013;185(4):309\u201316.","journal-title":"CMAJ Can Med Assoc J"},{"issue":"12","key":"6514_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2169\/internalmedicine.55.5553","volume":"55","author":"H Tsuji","year":"2016","unstructured":"Tsuji H, Ohmura K, Nakashima R, Hashimoto M, Imura Y, Yukawa N, et al. Efficacy and safety of grapefruit juice intake accompanying tacrolimus treatment in connective tissue disease patients. Intern Med. 2016;55(12):1547\u201352. https:\/\/doi.org\/10.2169\/internalmedicine.55.5553.","journal-title":"Intern Med"},{"issue":"2","key":"6514_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2133\/dmpk.21.122","volume":"21","author":"S Fukatsu","year":"2006","unstructured":"Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, et al. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokinet. 2006;21(2):122\u20135. https:\/\/doi.org\/10.2133\/dmpk.21.122.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"6514_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0009-9236(99)70102-5","volume":"65","author":"DJ Edwards","year":"1999","unstructured":"Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, et al. 6\u2032,7\u2032-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther. 1999;65(3):237\u201344. https:\/\/doi.org\/10.1016\/S0009-9236(99)70102-5.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"6514_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jfda.2016.11.008","volume":"25","author":"WL Hung","year":"2017","unstructured":"Hung WL, Suh JH, Wang Y. Chemistry and health effects of furanocoumarins in grapefruit. J Food Drug Anal. 2017;25(1):71\u201383. https:\/\/doi.org\/10.1016\/j.jfda.2016.11.008.","journal-title":"J Food Drug Anal"},{"issue":"1","key":"6514_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/foods10010033","volume":"10","author":"Z Petric","year":"2020","unstructured":"Petric Z, \u017duntar I, Putnik P, Bursa\u0107 KD. Food-drug interactions with fruit juices. Foods. 2020;10(1):33.","journal-title":"Foods"},{"issue":"4","key":"6514_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1124\/dmd.105.007930","volume":"34","author":"H Kim","year":"2006","unstructured":"Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, Liu KH. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab Dispos. 2006;34(4):521\u20133. https:\/\/doi.org\/10.1124\/dmd.105.007930.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"6514_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.xphs.2024.10.037","volume":"114","author":"K Koinuma","year":"2025","unstructured":"Koinuma K, Noto K, Morita T, Uekusa Y, Kikuchi H, Shimoji M, et al. Kinetics of the inhibition of CYP3A4 and CYP2C19 activity by jabara juice and identification of the responsible inhibitory components. J Pharm Sci. 2025;114(2):849\u201356. https:\/\/doi.org\/10.1016\/j.xphs.2024.10.037.","journal-title":"J Pharm Sci"},{"issue":"2","key":"6514_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/ajt.13495","volume":"16","author":"WS Oetting","year":"2016","unstructured":"Oetting WS, Schladt DP, Guan W, Miller MB, Remmel RP, Dorr C, et al. Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles. Am J Transplant. 2016;16(2):574\u201382. https:\/\/doi.org\/10.1111\/ajt.13495.","journal-title":"Am J Transplant"},{"issue":"1","key":"6514_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18\u201335. https:\/\/doi.org\/10.1038\/ajg.2016.517.","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06514-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06514-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06514-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:19:52Z","timestamp":1788808792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06514-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6514"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06514-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this case report in accordance with local and national guidelines, as it describes a single patient and involves no experimental intervention. Written and oral informed consent for participation and publication was obtained from the patient.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"522"}}